Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

Propanc Biopharma, Inc. announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen through the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program. The project was conducted in collaboration with the Universities of Jaén and Granada, Spain. The synthetic development of these proenzymes aims to create a backup clinical co..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

HiFiBiO Therapeutics Doses First Patient with HFB200301 in Combination with Tislelizumab for Advanced Solid Tumors

HiFiBiO Therapeutics has announced that the first patient has been dosed with HFB200301, a monoclonal antibody in combination with tislelizumab for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. The Phase 1a/b study will investigate the safety and tolerability of this combination therapy, and data from the trial w..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms